"Lilly and Incyte to seek approval of alopecia JAK inhibitor in children" was originally created and published by ...
While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.
The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback